Abstract
Introduction: Several Helicobacter pylori (HP) virulence factors are associated with the presence of more severe disease. The aim of the study was to investigate the association of antibodies against CagA, VacA, GroEL, gGT, HcpC and UreA with the risk of non-cardia gastric cancer.
Methods: Patient sample included individuals with histolopathologicaly proven gastric cancer (n = 128, median of age 67.5, males/females 84/44); control group was represented by consecutive dyspeptic patients coming or upper gastrointestinal endoscopy (n = 146, median of age 61, males/females 55/91) having no evidence of gastric mucosa atrophy, without HP eradication and proton pump inhibitor use during the previous month. Presence of CagA, VacA, GroEL, gGT, HcpC, and UreA antibodies was detected by line immunoassay based test on recombinantly expressed HP proteins (recomLine, Microgen, Germany). Statistical tests: chi2test, logistic regression.
Results: Antibodies against CagA, VacA, GroEL were significantly more often found among cancer patients compared to the control group (89% vs 65.1%; 21.9% vs 12.3%; 83.6% vs 63%, respectively). Seropositivity against different proteins in relation to risk for gastric cancer is shown in the Table 1.
Table 1 Seropositivity against different HP proteins in relation to risk for gastric
cancer
Odds ratio 95% Confidence interval p-value
CagA 4.371 2.280–8.382 0.001
VacA 1.991 1.042–3.804 0.035
GroEL 2.991 1.681–5.320 0.001
UreA 0.958 0.513–1.790 0.893
HcpC 1.546 0.914–2.614 0.103
gGT 1.204 0.740–1.958 0.454
CagA/VacA/GroEL 5.073 1.8653–13.79 0.001
Conclusions: Seropositivity against CagA, VacA and GroEL was associated with increased risk for non-cardia gastric cancer while individuals with triple positivity showed even fivefold increased risk of gastric cancer.
Methods: Patient sample included individuals with histolopathologicaly proven gastric cancer (n = 128, median of age 67.5, males/females 84/44); control group was represented by consecutive dyspeptic patients coming or upper gastrointestinal endoscopy (n = 146, median of age 61, males/females 55/91) having no evidence of gastric mucosa atrophy, without HP eradication and proton pump inhibitor use during the previous month. Presence of CagA, VacA, GroEL, gGT, HcpC, and UreA antibodies was detected by line immunoassay based test on recombinantly expressed HP proteins (recomLine, Microgen, Germany). Statistical tests: chi2test, logistic regression.
Results: Antibodies against CagA, VacA, GroEL were significantly more often found among cancer patients compared to the control group (89% vs 65.1%; 21.9% vs 12.3%; 83.6% vs 63%, respectively). Seropositivity against different proteins in relation to risk for gastric cancer is shown in the Table 1.
Table 1 Seropositivity against different HP proteins in relation to risk for gastric
cancer
Odds ratio 95% Confidence interval p-value
CagA 4.371 2.280–8.382 0.001
VacA 1.991 1.042–3.804 0.035
GroEL 2.991 1.681–5.320 0.001
UreA 0.958 0.513–1.790 0.893
HcpC 1.546 0.914–2.614 0.103
gGT 1.204 0.740–1.958 0.454
CagA/VacA/GroEL 5.073 1.8653–13.79 0.001
Conclusions: Seropositivity against CagA, VacA and GroEL was associated with increased risk for non-cardia gastric cancer while individuals with triple positivity showed even fivefold increased risk of gastric cancer.
| Original language | English |
|---|---|
| Article number | P18.15 |
| Pages (from-to) | 163 |
| Number of pages | 1 |
| Journal | Helicobacter |
| Volume | 19 |
| Issue number | Suppl.1 |
| Publication status | Published - Sept 2014 |
| Event | 27th European Helicobacter and Microbiota Study Group (EHMSG) International Workshop: on Helicobacter & Microbiota in Inflammation & Cancer - Rome, Italy Duration: 11 Sept 2014 → 13 Sept 2014 Conference number: 27 https://www.ehmsg.org/_files/ugd/d8d367_047cb5fae7744b748619e95c65eb337e.pdf |
Field of Science*
- 3.1 Basic medicine
- 3.2 Clinical medicine
Publication Type*
- 3.3. Publications in conference proceedings indexed in Web of Science and/or Scopus database
